Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Monday, 04'th Nov 2024
Teva Pharmaceutical Industries (TEVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patien
TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positiv
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
10:20am, Friday, 01'st Nov 2024
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining
Teva Statement on European Commission Decision; Company to Appeal
07:30am, Thursday, 31'st Oct 2024
TEL AVIV, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is responding to the European Decision following its investigation into the company's
Teva fined $503 mln by EU for disparaging rival product
06:52am, Thursday, 31'st Oct 2024
The European Commission has fined Teva , the world's largest generic drugmaker, 462.6 million euros ($503 million) for abusing its dominant position to delay competition to its blockbuster multiple sc
Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know
10:56am, Friday, 25'th Oct 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 25.1% in Teva Pharmaceutical Industries (TEVA). While the effectiveness of this highly sought-after metric is q
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
10:46am, Wednesday, 23'rd Oct 2024
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
10:46am, Wednesday, 23'rd Oct 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
12:59am, Wednesday, 23'rd Oct 2024
Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing drugs on
REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
3 Attractive Biotechs With Recent Positives
04:17pm, Monday, 21'st Oct 2024
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
03:47pm, Friday, 18'th Oct 2024
Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Dise
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
11:07am, Thursday, 17'th Oct 2024
On Thursday, Amicus Therapeutics FOLD announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. TEVA.
Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says
04:18pm, Thursday, 10'th Oct 2024
New Jersey-based drugmaker Teva has agreed to pay $450 million to resolve allegations that it violated an anti-kickback statute and the False Claims Act, the U.S. Justice department said in a statemen
